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SERIAL CHANGES IN SERUM AND FECAL BIOMARKERS LEVELS IN 
PEDIATRIC PATIENTS WITH IBD TREATED WITH REMICADE 
JULIANA MARIA ZAPATA 
ABSTRACT 
Introduction: Patients with Inflammatory Bowel Disease (IBD) undergo costly and 
invasive procedures in efforts to both diagnose and monitor their disease. Healthcare 
providers rely on endoscopic and radiologic studies, mucosal biopsies, and biochemical 
testing to stage a particular patient’s disease type and severity. Efforts to lower both the 
cost and morbidity associated with these evaluations are in demand, especially with 
respect to testing in pediatric patients. Serum and fecal biomarkers hold great potential in 
providing non-invasive, cost effective, and safer methods of diagnosis and assessment of 
IBD disease activity, and numerous serum and fecal biomarkers are currently under 
investigation. Serum biomarkers have proven useful in assessing systemic inflammation.  
However, by nature, changes in these levels of these serologic biomarkers do not 
necessarily reflect changes in specific inflammatory disorders, including those occurring 
in the gastrointestinal (GI) tract. In contrast, fecal biomarkers provide information that is 
more specific to the GI tract. Nonetheless, there are still many questions regarding 
whether serum and fecal biomarkers display sufficient sensitivity and specificity for 
distinguishing between patients with Crohn disease (CD) and ulcerative colitis (UC), as 
well as for monitoring changes in disease state and therapeutic response. As such, further 
studies are needed to fully characterize the testing attributes of fecal and serum 
biomarkers of IBD. 
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Methods: We recruited pediatric patients with either CD or UC in the inpatient and 
ambulatory settings at Boston Children’s Hospital.  All patients were naïve to Remicade 
at the time of enrollment. The objective of the study was to collect baseline stool and 
serum samples during their first Remicade infusion as well as at all follow up infusions. 
Serum samples were analyzed for C-reactive protein (CRP), lactoferrin, Anti–
Saccharomyces cerevisiae antibody (ASCA) levels, and for Erythrocyte Sedimentation 
Rate (ESR). Stool samples were analyzed for lactoferrin, calprotectin, ASCA, and 
hemoglobin levels. 
 
Results: Of the first two patients consented for the study, one provided a stool and serum 
sample at their first infusion and a serum sample at their second and the other provided a 
stool and serum sample at their second infusion. In both patients, clinical blood work was 
completed at the time of both infusions, allowing for analyses of changes in CRP and 
ESR. In patients with CD and UC, serum levels of CRP and ESR were both lower at the 
time of their second Remicade infusion. In addition, serum lactoferrin levels were lower 
in patients with CD at the time of their second Remicade infusion. Fecal and serum 
ASCA was not detectable in any of the samples collected. 
 
Conclusions: Our findings demonstrate the potential that fecal biomarkers hold for 
assessing therapeutic response to Remicade. Additional studies with larger sample sizes 
will be necessary to confirm these findings, as well as to explore our secondary objective 
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of determining whether individual or combination of biomarkers can help to distinguish 
patients with CD from those with UC.  
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INTRODUCTION 
Inflammatory Bowel Disease 
Inflammatory Bowel Disease (IBD) is an umbrella term that includes several 
idiopathic autoimmune diseases that affect the gastrointestinal tract. The pathogenesis of 
IBD is not fully understood, but likely is a manifestation of an excessive immune 
response to resident luminal bacterial flora in genetically susceptible individuals. The 
most prevalent forms of IBD include Crohn disease (CD) and ulcerative colitis (UC) 
(Khor, Gardet, & Xavier, 2011).  Patients with clinical pictures that make it difficult to 
discriminate their disease between CD and UC are referred to as having indeterminate 
colitis (IC). IBD afflicts one in 200 people in developed countries, and displays a rising 
prevalence in developing countries. Patients with IBD can experience intermittent 
episodes of abdominal pain, diarrhea, rectal bleeding, vomiting, and lethargy. The 
chronicity of these symptoms, especially if unrecognized or undermanaged, can lead to 
poor psychosocial wellbeing, as well as a negative impact on academics, employment, 
relationships, and sexual health (Cleynen et al., 2016). Currently, the diagnosis and 
management of patients with IBD is both invasive and costly, and it relies on serial 
endoscopic examination and microscopic assessment of relevant mucosal biopsies. For 
this reason, there are ongoing efforts to discover and validate less invasive approaches to 
assess disease progression and therapeutic response in patients with IBD. Findings from 
these studies may also help to stratify patients with respect to which treatments they are 
most likely to benefit. 
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IBD affects approximately 1.4 million Americans (Loftus & Sandborn, 2002). 
The incidence of IBD has been traditionally higher in developed countries.  However it is 
now becoming increasingly common in developing countries (Ponder & Long, 2013). 
These findings suggest that environmental factors common to the “Western” lifestyle 
may contribute to the development of IBD. Further support for this hypothesis comes 
from the observation that individuals moving from an area with lower incidence of IBD 
to one of higher incidence are at greater risk of developing the disease (Ponder & Long, 
2013). 
CD and UC are typically diagnosed in patients between 15-30 years of age, with a 
later incident peak occurring in the fifth and sixth decades. Age and gender seem to have 
an impact on the incidence of IBD. Pediatric patients have a higher incidence of CD than 
UC, and the mean age at diagnosis of UC is 5-10 years later than in CD. Male pediatric 
patients seem to have higher incidence of CD, although there is no such bias in the 
incidence of UC. The gender of adult patients does not appear to impact the incidence of 
either form of IBD (Sauer & Kugathasan, 2010). 
The etiopathogenesis of IBD is not completely understood. Existing evidence 
suggests that IBD likely results from an interplay between patient diet, immunity, 
environmental exposures and, most importantly, genetics (Connelly et al., 2015; Halmos 
& Gibson, 2015; O’Toole & Korzenik, 2014; Roggenbuck et al., 2016). Several studies 
have shown a higher concordance of IBD in monozygotic versus dizygotic twins.  This is 
especially relevant in patients with CD, in which the concordance rate was as high as 
39%, compared to the 7% recorded in monozygotic twins. The corresponding figures for 
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UC were 15% and 4%, respectively. Furthermore, first-degree relatives of patients with 
IBD are up to 10 times more likely to develop IBD than their counterparts in the general 
population. The higher concordance rate in CD patients suggest that environmental 
exposures may be playing a more prominent role in precipitating or maintaining the 
immune response in patients with UC compared to CD (Spehlmann et al., 2008). Some 
data suggest that genetics may play a greater role in the development of early-onset 
pediatric CD, as opposed to UC. Some environmental risk factors implicated in the risk 
for IBD include breastfeeding, vitamin D levels, pet exposure, smoking, and antibiotic 
use. The accumulated environmental exposure of an individual, a concept termed the 
exposome, is thought to shape the probability of developing a number of acquired 
autoimmune diseases, including IBD, over the course of a patient’s lifetime (Anaya, 
Ramirez-Santana, Alzate, Molano-Gonzalez, & Rojas-Villarraga, 2016). 
As noted earlier, a “Western” lifestyle appears to place individuals at an increased 
risk for the development of IBD. The hygiene hypothesis is one explanation to account 
for this observation. It suggests that the more sterile environments found in western 
society may play an important role in the rising prevalence of IBD. The interactions of 
the immune system with microbes contributes to the development of a well-regulated, 
tolerogenic environment for commensal microbiota, while at the same time maintaining 
the ability of the GI mucosal immune system to recognize and combat luminal pathogens. 
When the immune system encounters fewer pathogenic microbes in a more sterile, 
environment, it may develop improperly or incompletely and this can result in 
inappropriate responses to commensal bacteria (Ponder & Long, 2013). Other hypotheses 
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for the difference in prevalence between developed and undeveloped countries is 
centered on the possibility that a Western diet may select for particular bacteria or 
bacterial genres that contribute to the development of IBD (Benchimol, To, Griffiths, 
Rabeneck, & Guttmann, 2011). 
The mucosa lining the gastrointestinal tissue is one of several areas in the body 
that interacts directly with the outside environment and therefore is the location of some 
of the most extensive immunological processes. Gut-associated lymphoid tissue (GALT) 
consists of numerous structures that both monitor the epithelial barrier as well as 
differentiate between commensal and pathogenic bacteria. In healthy individuals, their 
commensal intestinal flora, made up of a composite of bacteria, viruses, and fungi, exists 
in homeostasis with the host immune system (Alarcón, González, & Castro, 2016). 
However, in patients with IBD, this homeostasis is disturbed and a pathological 
interaction ensues. This can manifest as defects in the epithelial barrier function, which in 
turn will result in both an increased exposure of the intestine with the outside 
environment, and pathogenic invasion that can further incite the host immune response. 
The cycle of inflammation results in the chronic damage observed in histological 
examinations of patients with IBD (C. Abraham & Cho, 2009). 
Diagnosis and differentiation of Crohn Disease and Ulcerative Colitis 
 The diagnosis of IBD is established through a combination of clinical history, 
endoscopic results, and histopathology. The mucosal inflammation observed in patients 
with UC is limited to the mucosa and is classified according to its extent. UC 
inflammation typically begins in the rectum and extends, in a contiguous fashion, to 
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involve some/all of the large intestine. In patients with proctitis, inflammation is limited 
to the rectum. Inflammation that does not extend beyond the splenic flexure is termed 
left-sided colitis.  Disease extending beyond the splenic flexure is termed pan-colitis. 
Clinical symptoms of UC can include diarrhea, rectal bleeding, and abdominal 
tenderness. The precise combination of symptoms depends on the degree of 
inflammation, as well as its extent. In patients with proctitis, rectal bleeding is the most 
predominant symptom.  In patients with extensive or left-sided colitis, the main symptom 
is bloody diarrhea. In severe cases, pure blood and passage of pus may occur. 
In contrast to UC, the mucosal inflammation observed in patients with CD can 
affect any part of the gastrointestinal tract, and the inflammation can be non-continuous. 
CD is phenotyped using the Paris classification, which characterizes a patients along 
dimensions of age at diagnosis, disease localization, and behavior (mucosal, penetrating, 
and stricturing) (Louis, Van Kemseke, & Reenaers, 2011). The inflammation in patients 
with CD can be transmural, whereas in UC the inflammation is generally confined to the 
mucosa. Symptoms of CD depend on localization and behavior of the disease including 
fatigue, diarrhea, abdominal pain, weight loss, and fever. Unlike UC, Crohn disease is 
generally linked with complications such as strictures, abscesses, and fistulas (Figure 1) 
(Khor et al., 2011). Patients with IBD are at increased risk for development of extra-
intestinal manifestations of IBD, including primary sclerosing cholangitis, ankylosing 
spondylitis, and psoriasis (Bernstein, Wajda, & Blanchard, 2005).  
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Figure 1: Types of complications arising from Crohn disease (Figure adapted from discovertherapies.com) 
 
Treatment Options 
Achieving clinical remission and maintaining that remittive state are the main 
goals of treatment in patients with IBD, as current medical treatment does not provide a 
cure. A variety of treatments exists, each with different advantages and disadvantages. 
Classically, the choice of treatment prescribed to an individual patient depends on which 
disease (UC or CD) they have, disease severity, and prior clinical history and response to 
therapy (Cleynen et al., 2016). There is considerable overlap between the exact 
therapeutics used. Here, we briefly review corticosteroids and several biological agents.  
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Corticosteroids 
 Corticosteroids have been a cornerstone in the treatment of patients with IBD 
since their introduction in the 1950s. They have proven their efficacy in inducing 
remission in patients with both UC and CD, but are not appropriate for maintaining 
remission. Thus, corticosteroids are typically used in the treatment of acute IBD or severe 
flares of disease symptoms. Some patients have disease that is refractory to steroids and 
require treatment with alternate drug classes. The optimal choice for treatment after a 
patient proves refractory to corticosteroid therapy is an area of active research.   
Biological Agents 
 Previous studies have demonstrated that Tumor-necrosis factor (TNF) plays a 
central role in the pathogenesis of both forms of IBD. Infliximab, or Remicade, was the 
first approved anti-TNF antibody-based treatment for UC (Figure 2). Two placebo-
controlled studies demonstrated that an induction regimen of Remicade infusion, 
followed by maintenance treatment every 2 months, was superior in achieving remission 
and mucosal healing compared to placebo in moderate to severe UC (Wilhelm, 
McKenney, Rivait, & Kale-Pradhan, 2008). A study evaluating adalimumab (Humira), a 
humanized anti-TNF therapy, demonstrated similar results in treating patients with 
moderate to severe UC, with rates of clinical remission at week 8 measured at 16.5%,  
compared to 9.3% in patients treated with a placebo (Sandborn et al., 2012). 
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Figure 2: Remicade action. 
 There are currently three commercially available antibodies to TNF that have 
been approved by the Food and Drug Administration (FDA) for use in the treatment of 
Crohn disease. Remicade was first accepted for inducing remission in CD patients with 
non-fistulizing disease, after study results demonstrated that 58% of patients responded to 
the induction dose, and significantly more were in remission in the Remicade-treated 
group compared to the placebo group (Reinisch, Wang, Oddens, & Link, 2012). 
Remicade has also shown efficacy in the treatment of patients with fistulizing Crohn 
disease, in which it was effective in the closure of draining fistulas and increased the 
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chance of sustained response during maintenance therapy (Kawalec, Mikrut, Wiśniewska, 
& Pilc, 2013). In contrast to Remicade, which requires infusions every 4-8 weeks, 
Humira has the advantage of being administered subcutaneously and at home every 2 
weeks. Humira has demonstrated efficacy in the treatment of patients with moderate to 
severely active Crohn disease (Viola et al., 2009). However, the efficacy of Humira in 
treating fistulizing CD has only been evaluated in subgroup analyses. As such, Humira is 
not indicated for use in the treatment of patients with fistulas. The most recent anti-TNF 
agent approved for use in the treatment of patients with Crohn disease is Certolizumab 
pegol (Cimzia), which has been approved for use in the United States, but not in the 
European Union. There have not been, as of yet, any randomized head-to-head studies 
directly comparing the efficacy of the three therapies in the treatment of patients with 
IBD. 
Biomarkers 
 The term biomarker refers to a quantitative indicator, generally used in place of a 
more invasive or costly assay, to assess biological or pathogenic processes as well as 
pharmacological responses to therapeutics. Biomarkers can be employed in a variety of 
healthcare sectors, and have found widespread use as endpoints in clinical trials. Ideally, 
the goal is to develop biomarkers that will enable clinicians to proactively change therapy 
before a patient develops clinical symptoms. In the context of IBD, biomarkers have been 
investigated as surrogates for endoscopic assessment by providing accurate and objective 
noninvasive measures of mucosal inflammation. It is important to note that while 
biomarkers may signify a change in biological processes, they are not the actual outcome 
 10 
in question. As such, it is critical that any biomarker be validated for use to answer any 
specific clinical question. 
Serum and Fecal Biomarkers in IBD 
 Serum and fecal biomarkers are being explored to more easily and less invasively 
diagnose and assess disease states. Serum biomarkers are most useful for detecting 
systemic, non-specific inflammation and include both C-reactive protein (CRP) and 
Erythrocyte Sedimentation Rate (ESR). CRP is a protein that is produced by the liver in 
response to IL-6 stimulation and released into circulation. Serum CRP levels are 
therefore, non-specific and cannot be used by themselves to diagnose or monitor disease 
activity in patients with IBD. Increased ESR can also reflect increased inflammation but 
has a similar drawback in lacking specificity (Cioffi, Rosa, Serao, Picone, & Vietri, 
2015). Fecal biomarkers, on the other hand, can provide more specific information with 
respect to the presence of absence of inflammation in the gastrointestinal tract. Some 
fecal biomarkers of interest include fecal lactoferrin (FLA) and calprotectin, which have 
been previously shown to positively correlate with disease activity in patients with IBD 
(B. P. Abraham & Kane, 2012). While fecal biomarkers are more specific for assessing 
overall GI inflammation compared to serum markers, existing markers are unable to 
differentiate between different types of IBD (B. P. Abraham & Kane, 2012; Van Assche 
et al., 2011). Reducing or eliminating the need for endoscopy to diagnose and assess 
disease state in IBD patients is especially important in the case of pediatric patients (Van 
Assche et al., 2011).  
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Serum ASCA 
 Saccharomyces cerevisiae antibodies (ASCA) are specific anti-glycan antibodies 
directed against mannan in the cell wall of the yeast Saccharomyces cerevisiae.  ASCA is 
present in the serum of 50-60% of patients with CD and only in 5% of otherwise healthy 
control populations.  Interestingly, ASCA is found in up to 20-25% of first-degree 
relatives of patients with CD.  Serum ASCA levels appear to remain  stable over the 
course of the disease (Standaert-Vitse et al., 2009) and as such cannot be used to monitor 
disease activity. Serum ASCA has a sensitivity of 31-45% and a specificity of 90-100% 
in distinguishing patients with IBD from those presenting with non-inflammatory 
conditions with similar symptoms (Prideaux, De Cruz, Ng, & Kamm, 2012).  
 
Fecal ASCA 
Studies have demonstrated that increased serum ASCA may not be the result of 
increased intestinal permeability, but instead result from a decreased tolerance to 
commensal microbes existing in our bodies (Prideaux et al., 2012). ASCA is found in the 
stool of patients with IBD, and its levels there may provide more information for 
identifying and monitoring disease activity. Indeed, it was recently demonstrated that the 
AUC-ROC curve for using fecal ASCAs to identify patients with  CD is 0.62 for the 
(Tang et al., 2017).  
Fecal ASCA levels were significantly higher in patients with CD than in patients 
without CD, and higher still in patients with  CD who were most newly  diagnosed. 
Additionally, fecal ASCA levels were higher in CD patients versus patients with UC, 
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suggesting a role for this fecal biomarker in  distinguishing between UC and CD (Tang et 
al., 2017).  
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OBJECTIVES 
 Biomarkers hold great potential to provide non-invasive, less-expensive, and safer 
methods for diagnosing and assessing disease activity in patients with IBD. However, 
there are still many unanswered questions regarding whether biomarkers display 
sufficient sensitivity and specificity to be used longitudinally to determine changes in 
disease state and therapeutic response in particular patients. As such, studies are needed 
to further characterize the testing attributes of fecal ASCA and other potential stool 
biomarkers of intestinal disease.   
 The primary objective of this study is to examine changes in serum and fecal 
ASCA levels in a population of pediatric patients with IBD being treated with the anti-
TNF agent Remicade. Secondary objectives of this study are to examine differences in 
ASCA levels in subpopulations defined by disease type, as well as to determine if 
changes in ASCA levels can distinguish between patients with CD versus UC.  
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METHODS  
Study Participants 
 
 For this multicenter research study, pediatric IBD patients (≤21 years of age) were 
approached at Riley Children’s Hospital in Indianapolis and in the Center for Ambulatory 
Treatment & Clinical Research (CAT/CR) at Boston Children’s Hospital. In order to be 
eligible for the study, patients had to have been diagnosed with UC or CD. Patients were 
excluded if they had received Remicade infusions prior to the study. This study was 
reviewed and approved by the Institutional Review Board (IRB) at Boston Children’s 
Hospital (Protocol ID: IRB-P00023092). 
Recruitment procedure 
 Our goal is to recruit a total of 50 patients for this study. To date, two patients 
have been recruited, one with CD and one with UC. Their eligibility was established 
using clinical data collected in Power Chart®, an electronic medical record database. If a 
patient was eligible based on medical history, their primary provider was contacted to 
further confirm eligibility and ascertain whether it would be appropriate to approach 
them.  
Patients were approached during the course of their scheduled Remicade infusion 
appointments in the CAT/CR. Before starting the infusion, a Research Study Coordinator 
from the Inflammatory Bowel Disease Center introduced the study to the patient, and 
discussed the requirements, procedures, and objectives of the study. After answering 
questions thoroughly and given time to read the consent form, parental consent and 
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patient assent (patient <18 years) was obtained. Once enrolled in the study, patients were 
assigned a distinct study ID number to ensure their privacy.  
Study subjects were provided with stool collection materials including specimen 
cups, gloves, and biohazard bags.  Study subjects were instructed to bring in study stool 
specimens during subsequent Remicade infusions. Study subjects were also provided 
with a stool kit to mail back their initial stool sample. For every stool sample provided, 
the subject was reimbursed $35. The payments were logged in a Clinical Trial Subject 
Remuneration Log. In addition to providing a stool sample, about 5 mL of blood was 
collected in a venous blood collection tube (BD Vacutainer®) with a clot activator to 
process for serum. Lastly, the patient, if 7 years or older, also filled out an IMPACT III 
form, which is a self-reported quality of life questionnaire for children with IBD. 
Sample Processing 
After collection, the blood sample was immediately brought to a research lab 
located in the Enders Building at Boston Children’s Hospital and allowed 30 minutes to 
clot at room temperature. It was then spun at 3000 rpm in a centrifuge for 10 min at 25 
°C. The serum was divided in to two to three 1 mL aliquots in cryotubes. Study 
specimens were then labeled and stored at -80 °C until ready to be shipped to the testing 
facility, TECHLAB® Inc. (Blacksburg, Virginia). 
Stool samples were divided into three 2 mL aliquots, labeled, and stored in a -80 
°C freezer until ready for batch shipment to TECHLAB® Inc. 
Case Report Forms 
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 Research Electronic Data Capture (REDCap) was used to develop Case Report 
Forms (CRF) for use in this study (Figures 3-7). The use of these electronic password 
protected CRF’s facilitated the collection of standardized patient information from their 
medical record during the study. Because our study involved outside collaborators at 
Riley Children’s Hospital in Indianapolis, we did not include Protected Health 
Information (PHI) in the CRF to ensure patient privacy rights. CRF’s were divided into 
nine domains. The first section included demographic data collected at the time of the 
patient’s first infusion. The information abstracted for inclusion in the subsequent eight 
sections included medications, disease location, Paris classification, infusion data, any 
special testing and quality of life indices including Parent Pedsql and Child Pedsql.  
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Figure 3: CRF 1: demographic data, Paris classification, Parent PedsQL. 
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Figure 4: CRF 2: Child PedsQL, Medications, Disease data, and Infusion Data. 
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Figure 5: CRF 3: Infusion data. 
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Figure 6: CRF 4: Infusion data and Enrollment and special testing. 
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Figure 7: CRF 5: Subsequent Colonoscopies. 
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RESULTS 
 
Patient Population 
 
Our analyses to date included data collected from 2 patients (1 with CD and 1 
with UC), who provided informed consent for participation in the study. IMPACT III 
surveys were filled out by all patients and were included in the data analysis along with 
the biomarker data. Of the 2 patients from Boston Children’s who had their biomarker 
data included in this thesis, the patient with CD provided a stool and serum sample at 
their first infusion and the UC patient provided a stool sample at their second infusion, 
and both patients provided a serum sample at their second infusion. 
 
Table 1. Demographic Information 
n 2 
UC 1 
CD 1 
UC phenotype  
Pancolitis 1 
CD phenotype  
Colon; penetrating 1 
UC  
Infusion 1 Stool Sample 0 
Infusion 1 Serum Sample 0 
Infusion 2 Stool Sample 1 
Infusion 2 Serum Sample 1 
CD  
Infusion 1 Stool Sample 1 
Infusion 1 Serum Sample 1 
Infusion 2 Stool Sample 0 
Infusion 2 Serum Sample 1 
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Changes in IMPACT III Scores with Remicade Treatment 
 
IMPACT scores improved in both study subjects during the interval between their 
first and second infusions, indicative of clinical response (Table 2). In both patients, the 
category that recorded the greatest improvement was that of bowel symptoms. Both 
patients also reported improvements in overall systemic symptoms, emotional 
functioning, and social functioning over their first two infusions. Only the UC patient 
saw improvements in body image. 
 
Table 2. IMPACT III Scores 
 Infusion 1 Infusion 2 
 Patient 1 
(CD) 
Patient 2 
(UC) 
Patient 1 
(CD) 
Patient 2 
 (UC) 
Bowel Symptoms  
(7-35) 
 
23 15 32 28 
Systemic Symptoms 
(3-15) 
 
8 8 12 11 
Emotional 
Functioning (7-35) 
 
19 20 21 23 
Social Functioning 
(12-60) 
 
47 42 51 45 
Body Image  
(3-15) 
 
9 12 9 14 
Treatment 
Intervention (3-15) 
 
10 8 10 11 
Total (35-175) 116 105 135 132 
 
Serum and Fecal ASCA Levels in IBD Patients 
 
We were unable to detect the presence of ASCA in any of the serum or fecal 
samples from either the CD or UC patient. 
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Figure 8: CRP Levels at Remicade Infusions. This graph depicts CRP levels at CD and UC patients’ first and 
second infusion. There is a large decrease in CRP in both patients between their first infusion and their second 
infusion. 
 
Effect of Disease Type and State on C-reactive Protein Levels 
 
 Both patients had high (> 0.5 mg/dl) CRP levels at the time of their first infusion 
(Figure 8). In both patients, their CRP levels normalized by the time of their second 
infusion, with changes of -5.63 and -1.85 mg/dl for the CD and UC patient, respectively. 
The changes in CRP were inversely correlated with changes in four out of the six 
IMPACT III scores including Bowel Symptoms, Systemic Symptoms, Emotional 
Functioning, and Social Functioning, but not Body Image or Treatment Interventions for 
the CD patient and in all 6 IMPACT III scores for the UC patient. 
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Effect of Disease Type and State on Erythrocyte Sedimentation Rate 
 
 Both patients had a high (> 35 mm/hr) ESR at the time of their first infusion 
(Figure 9). Both patients also recorded a normalization in their ESR by the time of the 
second infusion, with changes of -45 and -21 mg/dl for the CD and UC patient, 
respectively. These changes in ESR was inversely correlated with changes in 4 out of the 
6 IMPACT III scores including Bowel Symptoms, Systemic Symptoms, Emotional 
Functioning, and Social Functioning, but not Body Image or Treatment Interventions. 
 
 
Figure 9: ESR at Remicade Infusions. This graph depicts ESR at the CD and UC patients’ first and second 
infusion. There is a large decrease in ESR in both patients between their first infusion and their second infusion. 
 
Effect of Disease Type and State on Serum and Fecal Lactoferrin Levels 
 
Data presented in Figure 10 and Figure 11 demonstrated changes in serum 
(Figure 10) and fecal (Figure 11) lactoferrin levels in the CD patient from their first and 
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second infusion versus the UC patient from their second infusion. The small sample size 
precluded the measurement of any tests of statistical significance.  
Given that the CD patient provided serum samples at both baseline and second 
infusions, we were able to calculate the change in lactoferrin over that time period. The 
level of this inflammatory marked dropped by 692 ng/g from the first to the second 
infusion (from 818.6 ng/g to 126.6 ng/g). This change in serum lactoferrin was inversely 
correlated with changes in 4 out of the 6 IMPACT III scores including Bowel Symptoms, 
Systemic Symptoms, Emotional Functioning, and Social Functioning, but not Body 
Image or Treatment Interventions. 
 
 
Figure 10: Serum Lactoferrin Levels at Remicade Infusions. This graph depicts serum lactoferrin levels at CD 
and UC patients’ first and, when available, second infusion.  
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Figure 11: Fecal Lactoferrin Levels at Remicade Infusions. This graph depicts fecal lactoferrin levels at the CD 
patient’s first infusion and at the UC patient’s second infusion.  
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Figure 12: Fecal Calprotectin Levels at Remicade Infusions. This graph depicts fecal calprotectin levels at the 
CD patient’s first infusion and at the UC patient’s second infusion.  
 
Fecal Calprotectin Levels in IBD Patients 
 
Data represented in (Figure 12 illustrates that fecal calprotectin levels measured at 
infusions one and two.  
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Figure 13: Fecal Hemoglobin Levels at Remicade Infusions. This graph depicts fecal hemoglobin levels at the 
CD patient’s first infusion and at the UC patient’s second infusion.  
 
Fecal Hemoglobin Levels in IBD patients 
 
Data presented in Figure 13 reflect the hemoglobin levels of subjects at the time of their 
first and second infusions. This biomarker demonstrated the greatest difference between 
the two disease types, and the patient with UC had a much lower hemoglobin than their 
counterpart with CD, even at the time of the second infusion.   
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DISCUSSION 
 The etiology of IBD has not been fully elucidated, and both genetic and 
environmental factors have been implicated.  The incidence of IBD is on the rise globally 
and represents an area of clinical care that needs improvement. Our ability to treat 
patients with IBD has improved significantly over the course of the past several decades, 
with more targeted therapies in widespread use. However, existing standards for 
diagnosis and disease monitoring are both invasive and costly. Nonetheless, healthcare 
providers require accurate and timely information on disease phenotype and severity to 
make the correct treatment decisions.  At the same time, clinical and translational 
research rely on accurate diagnostic laboratory, endoscopic, and histologic data to study 
whether different populations of patients with IBD are more or less likely to respond 
differently to different treatment alternatives. Serologic and fecal biomarkers of 
inflammation are currently being explored as a tool to help evaluate IBD patients. 
Elevations in serum biomarkers of inflammation including CRP and ESR are non-
specific and can be seen in the context of any local or systemic infectious, inflammatory, 
or rheumatologic process. In contrast, serum ASCA levels have demonstrated some 
efficacy in help to stratify patients into UC and CD diagnostic dichotomies (Cioffi et al., 
2015; Prideaux et al., 2012). More recent work has begun to explore the potential for 
fecal biomarkers to reflect more specifically the current inflammatory state of the GI 
tract. For instance, levels of fecal lactoferrin and fecal ASCA have been shown to provide 
some useful information with respect to  determining active vs non-active disease states 
as well as in differentiating patients between those with UC and those with CD (B. P. 
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Abraham & Kane, 2012; Tang et al., 2017). Further research exploring how reliably fecal 
and serum biomarkers can play a role in stratifying patients with respect to disease type 
and activity, and this should provide the reassurance to avoid ordering more invasive and 
costly procedures. 
The main objective of this study was to explore how serum and fecal biomarkers, 
particularly ASCA, respond to Remicade treatment in a population of pediatric patients 
with IBD. Our goal was to determine if serum or fecal biomarker levels have potential to 
reliably reflect therapeutic response.  Additional testing will also be necessary to define 
under which circumstances serum or fecal biomarker levels would be superior. The 
successfully application of fecal biomarkers could save patients from undergoing more 
invasive monitoring techniques to determine disease state.  In addition, changes in 
sensitive and specific fecal biomarker analysis may reduce the likelihood of continuing 
with treatment if their biomarker levels showed a lack of response to treatment. The hope 
was to give healthcare providers an additional, easier to use, tool with which they could 
observe disease progression and remission in patients. A sub goal of the study was to 
ascertain if there were differences in the biomarker levels between patients with UC and 
those with CD and if these differences could be exploited to help to distinguish between 
the two patient populations for the purpose of diagnosis. We were also interested as to 
whether or not using serum versus fecal biomarker levels for this purpose would be 
superior. This would potentially remove the need for endoscopic procedures, a goal made 
even more important in pediatric patient populations.  
 32 
We present here preliminary results and any conclusions drawn with regards to 
the objectives of the study.  We recognized that the small sample size precluded formal 
data analysis. The primary reason for the slow patient accrual was that the requirements 
for eligibility for patients as presented in this thesis may have been too restrictive. With 
increased sample size, we will be able to determine with greater certainty whether serum 
and fecal ASCA levels can be used to monitor disease state as well as whether they can 
be used to differentiate between UC and CD patient populations. The Center for 
Inflammatory Bowel Disease at Boston Children’s Hospital will continue to enroll 
patients in the study to expand the sample size.  
Another explanation for the low sample size in this study was due to patient 
compliance. While theoretically the logistics of collecting samples was simple due to the 
requirement for patients to visit the hospital to receive infusions, we had difficulty 
ensuring that patients brought in their stool sample. A difficulty in enrolling minor 
patients is that communication must be conducted through their guardians, so while 
reminder calls were attempted and emails were sent there was no guarantee that the 
patients would see them. 
 We saw improvements (increase) in total IMPACT III scores for both patients 
enrolled in this study. In both patients, the greatest increase was recorded in an 
improvement in bowel symptoms, suggesting that  Remicade in this patient was initially 
successful in treating the patients’ subjective opinion of their symptoms. Relative to the 
enrolled subject with CD, the patient with UC had a much lower bowel symptom score at 
their baseline infusion compared to that recorded at the time of their second infusion. The 
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data also suggests that Remicade successfully improved both patients’ subjective opinion 
of their systemic symptoms as well as their emotional and social functioning. 
We were unable to detect ASCA in either the fecal or serum sample from the CD 
patient at the time of their first infusion or the serum sample collected at the time of their 
second infusion.  Similarly, we did not detect fecal or serum ASCA in samples collected 
from the subject with UC. This lack of detection is consistent with previous data 
demonstrating that fecal ASCA is not present in every IBD patient.  As such, our study 
sample size at this point is much too small to make any sensitivity and specificity 
estimates with respect to the performance of ASCA within this patient population. 
There was a decrease in both CRP and ESR in both patients in the interval 
between their first and second infusions, suggesting a decrease in systemic inflammation. 
Together with their IMPACT III scores, these data suggest the potential for using these 
biomarkers to assess disease severity and response to treatment in both types of IBD 
patients. 
We observed a decrease in serum lactoferrin levels and an improvement in several 
IMPACT III dimension in the interval between the first and second infusion in the 
enrolled subject with CD. While the sample size is very small (n=1), the data trend is in 
concert with the hypotheses that: 1) Remicade infusions are effective; 2) changes in 
lactoferrin reflect changes in disease activity; 3) clinical improvement will be reflected in 
IMPACT III scores. The lack of a baseline stool sample precludes this type of 
preliminary analysis on data collected from the enrolled subject with UC. Nonetheless, 
we did observe an improvement in IMPACT III scores in the UC patient in the interval 
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between their first and second Remicade infusions. Clearly, more patients and increased 
compliance will be required to further support (or invalidate) our hypotheses. 
Fecal calprotectin and hemoglobin levels were only available from a single 
sample from each patient, one from the first infusion of the CD patient and one from the 
second infusion of the UC patient.  As such, no interpretation would be valid at this time.  
The preliminary data presented in this thesis was constrained due to the low 
patient enrollment across study center. Inclusion criteria were fairly stringent, and they 
required patients to be completely Remicade naïve. The number of patients starting 
Remicade was low, familiarity with the study was restricted among providers initially, 
and several potentially eligible had previously received Remicade. Furthermore, several 
potentially eligible patients were precluded by their insurance companies from receiving 
Remicade and had to receive an alternative medication, typically Humira.  
A conference call was initiated to address issues with delayed enrollment.  The 
result of these discussion lead to a modification of inclusion eligibility criteria.   We 
made these changes specifically to broaden our study population but not replace the focus 
of the study, which is to assess longitudinal changes (or stability) in fecal and serum 
biomarkers over time in a population of patients being treated with Remicade. These 
changes included enrolling: 
 Patients who has completed their loading dose of Remicade and were entering 
their maintenance phase (more than three infusions, but less than 6 months of 
aggregate therapy) 
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 Patients with recent changes in their Remicade dose (mg/kg) in response to a 
change in disease activity 
 A population of IBD patients who were clinically stable and receiving Remicade 
for the management of their CD or UC for more than 12 months 
The overall goal will be ten patients within each of these groups who have CD 
and 5 patients within each of these groups who have UC, for a total of 45 patients. This 
enrollment allocation was chosen in an effort to collect data from distinct patient 
populations in regards to treatment response. The first group will consist of newly 
diagnosed patients and those in the midst of a flare and needing changes in dose in 
response to changes in disease state or progression.  The addition of the third group will 
provide stability data to use as comparators to that collected from subjects drawn from 
other inclusion criteria. These subjects have typically demonstrated a consistent response 
to the treatment and operate from a locus in which they rarely have flares or need 
adjustments in their Remicade dosing. As such, data collected in this group will make 
possible an analysis of these biomarkers to assist healthcare providers to be able to 
predict if patients will be able to settle into a Remicade regimen long-term. This 
experimental design will provide the broadest data set that will both permit the 
assessment of the questions posed in this study, as well as to provide preliminary data for 
further controlled studies to assess the relationship(s) between changes in biomarker 
levels and ultimate clinical outcome.  
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FUTURE DIRECTIONS 
The low patient enrollment limited our ability to complete a lengthy preliminary 
data analysis.  Recent changes in inclusion criteria should remedy this situation.  
Ultimately we hope to use longitudinal changes in fecal and serum biomarker levels to 
determine if there exists a statistical difference in either the changes in biomarker levels 
observed after and during Remicade treatment as well as whether there is a statistical 
difference in biomarker levels between CD and UC patient populations.  
The third group of patients, those who have been on Remicade for over a year, are 
distinct from the other groups in that they generally have shown a consistent response to 
the treatment and have settled into a regimen wherein they rarely have flares or need 
adjustments in dosage. Using this group, in conjunction with the others, we will be able 
to explore a number of additional questions including whether biomarker levels may 
differ in patients who develop or who have exhibited a long-term response to Remicade 
versus those who do not as a way for healthcare providers to be able to predict if patients 
will be able to settle into a Remicade regimen long-term. Finally, the expected, greater 
number of enrolled patients will allow us to explore other questions including whether 
biomarker levels can be predictive for an oncoming flare.  
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